The author(s) indicated no potential conflicts of interest. REFERENCES 1. Moll AC, Dommering CJ, Bosscha MI, et al: Risk factors for the incidence of second cancers in survivors of retinoblastoma with a family history. J Clin Oncol 30:3028, 2012 2. Rushlow D, Piovesan B, Zhang K, et al: Detection of mosaic RB1 mutations in families with retinoblastoma. Hum Mutat 30:842-851, 2009 3. Sippel KC, Fraioli RE, Smith GD, et al: Frequency of somatic and germ-line mosaicism in retinoblastoma: Implications for genetic counseling. Am J Hum Genet 62:610-619, 1998 4. Kleinerman RA, Yu CL, Little MP, et al: Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol 30:950-957, 2012 Abbreviation: RR, relative risk. Correspondence www.jco.org
571 Background: Preclinical studies have shown that cell lines and murine models of TNBC phenotype are more sensitive to PARP1 inhibitors. This evidence provides strong rationale for developing a new therapeutic approach to TNBC based on targeting the DNA-repair defects via PARP inhibition. Methods: The purpose of this study was to report the Maximal Tolerated Dose (MTD) of Olaparib (O) administered concurrently with locoregional RT and evaluate the Dose-Limiting Toxicity (DLT). Results: Twenty-four pts with performance status 0-1 were enrolled between 09/2017 and 11/2019. Of them, 21 underwent adjuvant RT-O because poor response to NAC, and 3 received preoperative RT+O because of progression after NAC. The patients’ profile is given in table. All patients received full course RT-O, as following: 4 pts at dose 50mg bid; 8 at 100x2; 7 at 150x2, and 5 at 200x2. No DLT was observed. Two pts (8.7%) experienced acute grade 3 dermatitis no grade 4 toxicities related to the RT were observed. The O-related toxicity was acceptable with mostly grade 1-2 symptoms. The only grade 3-4 hematological toxicity was lymphopenia in 11 cases. Conclusions: Dose of O was escalated to the target dose of 200 mgx2, without DLT. Further follow up is needed to evaluate the late toxicities. Clinical trial information: NCT03109080 . [Table: see text]
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.